Luteolin research exhibits sustained growth, with a significant increase after 2021. Research focus has expanded from early antioxidant and anti-inflammatory mechanisms to metabolic health, immune regulation, tumor suppression, and multisystem protection. Network pharmacology identified 239 potential targets, with core targets including TP53, TNF, STAT3, and EGFR, significantly enriched in p53, PI3K-Akt, TNF, and IL-17 pathways. Disease association networks indicate luteolin's potential to intervene in neurological, circulatory, metabolic, immune, digestive, respiratory disorders, and multiple tumors, exhibiting typical multi-target comprehensive regulatory characteristics.
Guo et al. (Wed,) studied this question.